Engineered immune cells take aim at childhood autoimmune diseases
NCT ID NCT07674147
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goal is to check safety, but researchers will also look for signs of disease improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RD06-05 (universal CD19/BCMA-targeted CAR-T cell injection)
What this could lead to
If successful, this could offer a new treatment option for children with hard-to-treat autoimmune diseases, potentially reducing disease activity and need for ongoing medications.
What could go wrong
This is a very early, small study (30 participants) focused on safety. CAR-T therapy carries serious risks like cytokine release syndrome, neurotoxicity, and infections. It may not work for all patients or diseases tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing Children's Hospital
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••